CJC-1295 + Ipamorelin Stack

The synergy between CJC-1295 and Ipamorelin stems from their complementary mechanisms of action within the growth hormone axis. CJC-1295 functions as a growth hormone-releasing hormone (GHRH) analogue, binding to GHRH receptors in the anterior pituitary and stimulating sustained growth hormone release. Its drug affinity complex (DAC) modification extends its half-life significantly, allowing for less frequent dosing whilst maintaining elevated growth hormone levels.

Ipamorelin, conversely, works as a selective growth hormone secretagogue receptor (GHSR) agonist. It mimics ghrelin's action, triggering growth hormone release through a different pathway entirely. This selectivity means Ipamorelin doesn't significantly affect cortisol or prolactin levels, unlike other growth hormone secretagogues.

When combined, these peptides create a dual-pathway stimulation approach. CJC-1295 provides the sustained baseline elevation of growth hormone through GHRH receptor activation, whilst Ipamorelin delivers more immediate, pulsatile releases that mirror natural growth hormone secretion patterns. Research suggests this combination may produce up to 200-300% increases in growth hormone levels compared to baseline.

The timing synergy is particularly noteworthy. CJC-1295's extended half-life means it continues working whilst Ipamorelin provides additional pulses, creating a more physiologically natural pattern of growth hormone release. This approach may help preserve the body's natural feedback mechanisms whilst maximising the anabolic and recovery benefits associated with optimised growth hormone levels.

CJC-1295 Dosing:

• Dose: 1-2mg per injection
• Frequency: 2-3 times per week
• Timing: Evening before bed (ideally 2-3 hours post-meal)

Ipamorelin Dosing:

• Dose: 200-300mcg per injection
• Frequency: 1-3 times daily
• Timing: Upon waking (fasted), pre-workout, and/or before bed

Injection Protocol: Both peptides should be administered subcutaneously using insulin syringes. Rotate injection sites between abdomen, thighs, and upper arms to prevent lipodystrophy. Always inject on an empty stomach (at least 2 hours post-meal) and avoid eating for 20-30 minutes post-injection to maximise effectiveness.

For reconstitution guidance, refer to our reconstitution guide to ensure proper preparation and storage.

Cycling Protocol:

• Beginner cycle: 8-12 weeks on, 4-6 weeks off
• Advanced cycle: 16-20 weeks on, 8-10 weeks off

Sample Daily Schedule:

• Morning: Ipamorelin 250mcg (fasted)
• Evening: CJC-1295 1.5mg + Ipamorelin 250mcg (2-3 hours post-dinner)

Storage: Both peptides require refrigeration at 2-8°C once reconstituted. Use bacteriostatic water for reconstitution and consume within 30 days. Always maintain sterile technique and use fresh needles for each injection.

Consider using our cost calculator to estimate your monthly expenditure based on your chosen dosing protocol.

Weeks 1-2: Initial adaptations typically include improved sleep quality and faster recovery between training sessions. Some users report enhanced mood and mental clarity. Growth hormone levels begin elevating, though physical changes remain minimal.

Weeks 3-4: More noticeable improvements in sleep architecture, with deeper, more restorative sleep patterns. Enhanced recovery becomes apparent, with reduced muscle soreness and improved training capacity. Skin quality may begin improving with enhanced elasticity and hydration.

Month 2: Visible body composition changes emerge. Users typically report modest increases in lean muscle retention and gradual fat loss, particularly around the midsection. Enhanced energy levels throughout the day become consistent. Hair and nail growth may accelerate.

Month 3 and beyond: Peak benefits typically manifest around the 8-12 week mark. Research suggests users may experience 5-10% improvements in body composition, enhanced muscle definition, and continued sleep quality benefits. Long-term users report sustained energy improvements and enhanced overall well-being.

Results vary significantly based on individual factors including age, baseline hormone levels, diet quality, training consistency, and sleep habits. Those with lower baseline growth hormone levels typically experience more pronounced benefits.

Both peptides in this stack generally exhibit favourable safety profiles, though potential side effects warrant consideration. Common mild side effects include injection site reactions such as redness, swelling, or itching, typically resolving within 24-48 hours.

CJC-1295-specific effects may include water retention, particularly in hands and feet, joint discomfort, and occasional headaches during initial weeks. Some users report increased appetite and vivid dreams due to enhanced sleep quality.

Ipamorelin-specific effects are typically minimal but may include mild nausea when taken on an empty stomach, temporary flushing, or slight dizziness immediately post-injection.

Contraindications include pregnancy, breastfeeding, active cancer, and uncontrolled diabetes. Individuals with pituitary disorders, severe heart conditions, or taking medication for growth hormone deficiency should avoid this stack.

Before beginning any peptide protocol, understand the current UK legal status regarding peptide possession and use. These substances are not approved for human consumption and are sold strictly for research purposes.

Always consult healthcare professionals before starting any peptide regimen, particularly if you have pre-existing medical conditions or take medications. Regular health monitoring including blood work is advisable during extended cycles.